nach oben

European Journal of Nuclear Medicine and Molecular Imaging

29.04.2024 | Editorial

Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI.

verfasst von: Irene Gotuzzo, Riemer H.J.A. Slart, Alessia Gimelli, Nabila Ashri, Constantinos Anagnostopoulos, Jan Bucerius, Ronny R. Buechel, Oliver Gaemperli, Olivier Gheysens, Andor W.J.M. Glaudemans, Gilbert Habib, Fabian Hyafil, Mark Lubberink, Antti Saraste, Tomaz Podlesnikar, Marc R. Dweck, Paola A. Erba

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Excerpt

Cardiac amyloidosis (CA) is an infiltrative and restrictive cardiomyopathy that might rapidly lead to heart failure if left untreated. The prognosis is variable and depends on the type of cardiac amyloidosis, but the end stages are associated with poor outcomes and the disease is often associated with important morbidity and reduced quality of life. …

Nur mit Berechtigung zugänglich

Ihne S, Morbach C, Sommer C, Geier A, Knop S, Störk S. Amyloidosis-the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int. 2020;117(10):159–66. https://doi.org/10.3238/arztebl.2020.0159CrossRefPubMedPubMedCentral

Arcana RI, Crișan-Dabija R, Cernomaz AT, et al. The risk of sarcoidosis misdiagnosis and the harmful effect of corticosteroids when the disease picture is incomplete. Biomedicines. 2023;11(1). https://doi.org/10.3390/biomedicines11010175

Ikeda U, Editorial. Diagnosis of cardiac sarcoidosis - what is the role of endomyocardial biopsy? J Cardiol Cases. 2015;12(3):72–3. https://doi.org/10.1016/j.jccase.2015.05.015CrossRefPubMedPubMedCentral

Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8(9):712–24. https://doi.org/10.1016/j.jchf.2020.04.007CrossRefPubMedPubMedCentral

Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–50. https://doi.org/10.1016/j.carpath.2015.07.008CrossRefPubMed

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612CrossRefPubMed

Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368–83. https://doi.org/10.1016/j.jcmg.2019.07.015CrossRefPubMed

Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45(11):1945–55. https://doi.org/10.1007/s00259-018-4013-4CrossRefPubMed

Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344–50. https://doi.org/10.1093/ehjci/jew325CrossRefPubMed

10.

Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880–9. https://doi.org/10.1001/jamacardio.2016.2839CrossRefPubMed

11.

Tingen HSA, Tubben A, van ’t Oever JH, et al. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2023;51(1):93–109. https://doi.org/10.1007/s00259-023-06381-3CrossRefPubMedPubMedCentral

12.

Slart RHJA, Glaudemans AWJM, Hazenberg BPC, Noordzij W. Imaging cardiac innervation in amyloidosis. J Nucl Cardiol. 2019;26(1):174–87. https://doi.org/10.1007/s12350-017-1059-9CrossRefPubMed

13.

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14(7):e000029. https://doi.org/10.1161/HCI.0000000000000029CrossRefPubMed

14.

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. Circ Cardiovasc Imaging. 2021;14(7):e000030. https://doi.org/10.1161/HCI.0000000000000030CrossRefPubMed

15.

Cuscaden C, Ramsay SC, Prasad S, Goodwin B, Smith J. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2021;28(6):2845–56. https://doi.org/10.1007/s12350-020-02152-xCrossRefPubMed

16.

Saric P, Young KA, Rodriguez-Porcel M, Chareonthaitawee P. PET imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers. Pharmaceuticals (Basel). 2021;14(12). https://doi.org/10.3390/ph14121286

17.

Genovesi D, Bauckneht M, Altini C, et al. The role of positron emission tomography in the assessment of cardiac sarcoidosis. Br J Radiol. 2019;92(1100):20190247. https://doi.org/10.1259/bjr.20190247CrossRefPubMedPubMedCentral

18.

Sperry BW, Tamarappoo BK, Oldan JD, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):336–45. https://doi.org/10.1016/j.jcmg.2017.04.020CrossRefPubMed

19.

Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–36. https://doi.org/10.1016/j.jacc.2013.09.022CrossRefPubMed

20.

Writing group, Document reading group, Reviewers EACVI. This document was reviewed by members of the EACVI Scientific Documents Committee for 2014–2016 and 2016–2018. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging. 2017;18(10):1073–89. https://doi.org/10.1093/ehjci/jex146CrossRef

21.

Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017;58(8):1341–53. https://doi.org/10.2967/jnumed.117.196287CrossRefPubMedPubMedCentral

22.

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626. https://doi.org/10.1093/eurheartj/ehad194CrossRefPubMed

Titel: Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI.
verfasst von: Irene Gotuzzo
Riemer H.J.A. Slart
Alessia Gimelli
Nabila Ashri
Constantinos Anagnostopoulos
Jan Bucerius
Ronny R. Buechel
Oliver Gaemperli
Olivier Gheysens
Andor W.J.M. Glaudemans
Gilbert Habib
Fabian Hyafil
Mark Lubberink
Antti Saraste
Tomaz Podlesnikar
Marc R. Dweck
Paola A. Erba
Publikationsdatum: 29.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06727-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI.

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten